Biodexa Pharmaceuticals annual operating income
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Biodexa Pharmaceuticals Operating Income Growth & History (BDRX)
Biodexa Pharmaceuticals's operating income was −£8.6M for fiscal 2025.
View full Biodexa Pharmaceuticals company overviewBiodexa Pharmaceuticals annual operating income history
| Fiscal year | Period ended | Operating income | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | −£8.6M | £554,000 | — |
| 2024 | 2024-12-31 | −£9.2M | −£1.2M | — |
| 2023 | 2023-12-31 | −£8.0M | £918,000 | — |
| 2022 | 2022-12-31 | −£8.9M | −£1.9M | — |
| 2021 | 2021-12-31 | −£7.0M | £16.0M | — |
| 2020 | 2020-12-31 | −£23.0M | −£11.7M | — |
| 2019 | 2019-12-31 | −£11.3M | £497,000 | — |
| 2018 | 2018-12-31 | −£11.8M | £1.5M | — |
| 2017 | 2017-12-31 | −£13.3M | −£3.6M | — |
| 2016 | 2016-12-31 | −£9.7M | £3.3M | — |
| 2015 | 2015-12-31 | −£12.9M | — | — |
Biodexa Pharmaceuticals operating income trends
Over the last five fiscal years, Biodexa Pharmaceuticals's operating income increased from −£23.0M to −£8.6M, a change of £14.4M.
About the metric
What operating income means
Operating income is the profit or loss a company generates from its core business after cost of revenue and operating expenses, but before non-operating items such as interest and income taxes.
Calculation and source
SEC-reported operating income
TickerStat standardizes operating income reported in company SEC filings for aligned fiscal periods. It is not adjusted EBIT, an analyst estimate, or company guidance. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Biodexa Pharmaceuticals source filings ↗Community posts
Biodexa advances trial enrollment as research spending and cash use rise
Biodexa ($BDRX) reported that 92 of the planned 168 participants have entered its Serenta trial, while first-half research and development spending increased to £2.92 million from £1.67 million. Spending reflected the trial and manufacturin ...